When the first corporate disclosures under the European Union’s landmark Corporate Sustainability Reporting Directive (CSRD) began appearing in 2025, a critical examination of value chain social risk revealed a glaring disconnect across the financial sector. John E. Grova, a member of EFRAG’s Sustainability Reporting Technical Expert Group and a senior ESG adviser at SpareBank 1 […]
For decades, the pharmaceutical industry has relied heavily on animal models to test the safety and efficacy of emerging therapeutics. Yet, fundamental biological differences between species mean that a drug performing successfully in a mouse or a larger animal frequently fails when translated to human clinical trials. Most pharmaceutical candidates still ultimately fail during development, […]